Boundless Bio, INC

Boundless Bio's annual meeting saw the election of directors and ratification of its auditor, KPMG LLP.

Boundless Bio announced its first quarter 2026 financial results, highlighting progress in its KOMODO-1 clinical trial for BBI-940 and a cash runway extending into the second half of 2028.

Boundless Bio, Inc. has terminated its lease for approximately 80,168 square feet of laboratory and office space, effective May 31, 2026, incurring a $10.0 million lease modification payment and forfeiting a $0.5 million security deposit.

Boundless Bio announced its third quarter 2025 financial results, highlighting ongoing clinical trial enrollment and progress towards a new drug submission, supported by a cash runway into the first half of 2028.

Boundless Bio reported a reduced net loss in Q2 2025, alongside progress in its POTENTIATE clinical trial and BBI-940 development, with cash supporting operations into H1 2028.

Boundless Bio, Inc. announced that its stockholders elected two Class I directors and ratified KPMG LLP as its independent registered public accounting firm for 2025 at the annual meeting held on June 23, 2025.

Boundless Bio announces a merger with Serapha Bio, Inc., shifting focus to Serapha's Alpha-1 Antitrypsin Deficiency therapy and discontinuing its own ecDTx programs, while reporting increased net loss and significant workforce reduction.

Boundless Bio reports Q1 2026 results, detailing a net loss of $13.6 million, a strategic focus on BBI-940, and a significant lease termination and restructuring.

Boundless Bio reports reduced net losses and extended cash runway into H1 2028, driven by strategic portfolio prioritization and workforce reduction.

Boundless Bio, Inc. reported Q2 2025 results, revealing a strategic pipeline prioritization, workforce reduction, and an extended cash runway into the first half of 2028.

Boundless Bio, a clinical-stage oncology company, details its Q1 2025 financial results, highlighting ongoing research and development efforts in ecDNA-directed therapeutics.

Boundless Bio reported its Q3 2024 financial results, highlighting progress in its clinical programs and providing an update on its financial position, including a cash runway into the fourth quarter of 2026.

Boundless Bio's 2024 10-K filing highlights the company's focus on its lead drug candidate, BBI-355, currently in a Phase 1/2 clinical trial, and its Kinesin program, while also detailing financial results and future strategies.

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 17, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 14, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Boundless Bio, Inc. common stock on July 9, 2026.

Kevin Tang, a director and 10% owner of Boundless Bio, Inc., has acquired a significant number of common shares through various transactions in early July 2026.

Several directors and 10% owners of Boundless Bio, Inc. have reported transactions involving common stock and stock options.

ARCH Venture Funds report changes in beneficial ownership of Boundless Bio, Inc. common stock, including option exercises and share dispositions.

Boundless Bio, Inc. has issued a proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections and auditor ratification.

Boundless Bio will hold its annual stockholders meeting on June 23, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent auditor.

Boundless Bio will hold its 2025 Annual Meeting of Stockholders on June 23, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Boundless Bio is seeking to raise capital through an IPO to further develop its ecDNA-directed cancer therapies and diagnostic tools.

Boundless Bio, a clinical-stage oncology company, has filed an S-1 registration statement for an IPO, seeking to advance its novel ecDNA-directed therapies for oncogene-amplified cancers.

ADAR1 Capital Management and Daniel Schneeberger have filed a joint Schedule 13G, reporting beneficial ownership of 8.8% of Boundless Bio, Inc. common stock as of June 30, 2026.

Citadel entities have updated their beneficial ownership filings for Boundless Bio, Inc., reporting a combined 0.6% stake.

Tang Capital Management, LLC and affiliated entities have reported beneficial ownership of 11.3% of Boundless Bio, Inc.'s common stock.

FMR LLC and Abigail P. Johnson have reported a 12.0% beneficial ownership stake in Boundless Bio Inc's common stock as of December 31, 2025.

Citadel Advisors, Citadel Securities, and Kenneth Griffin have disclosed beneficial ownership of Boundless Bio, Inc. common stock, with Griffin holding 6.4% of the outstanding shares.

RA Capital Management and its affiliates have reported zero beneficial ownership in Boundless Bio, Inc., indicating a complete divestment of their prior holdings.